Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02389517 · OUTCOME

Progression Free Survival

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant · Source last updated 2026-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
years
Interval / dispersion
95% Confidence Interval
Time frame
up to 2 years

What was measured

Time to event will be estimated using the product-limit method of Kaplan and Meier.

Analysis population: One patient in Arm1 and two patients in Arm 2 were not analyzed because their data were not collected.

Groups in this outcome

Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)

Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only). Ixazomib Citrate: Given PO Lenalidomide: Given PO Dexamethasone: Given PO

Arm II (Lenalidomide)

Patients receive lenalidomide PO as in Arm I. Lenalidomide: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)19
Arm II (Lenalidomide)20

Reported measurements

Source class 1
Values in years · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)NANot reported2.2NAInsufficient number of participants with events to calculate via KM methodology
Arm II (Lenalidomide)NANot reportedNANAInsufficient number of participants with events to calculate via KM methodology
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Insufficient number of participants with events to calculate via KM methodology
        group Id
        OG000
        lower Limit
        2.2
        upper Limit
        NA
        value
        NA
      2. comment
        Insufficient number of participants with events to calculate via KM methodology
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    2. group Id
      OG001
      value
      20
    units
    Participants
description
Time to event will be estimated using the product-limit method of Kaplan and Meier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only). Ixazomib Citrate: Given PO Lenalidomide: Given PO Dexamethasone: Given PO
    id
    OG000
    title
    Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
  2. description
    Patients receive lenalidomide PO as in Arm I. Lenalidomide: Given PO
    id
    OG001
    title
    Arm II (Lenalidomide)
param Type
MEDIAN
population Description
One patient in Arm1 and two patients in Arm 2 were not analyzed because their data were not collected.
reporting Status
POSTED
time Frame
up to 2 years
title
Progression Free Survival
type
SECONDARY
unit Of Measure
years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice